Pfizer Net Change in Short-term Investments 2010-2025 | PFE
Pfizer annual/quarterly net change in short-term investments history and growth rate from 2010 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Pfizer net change in short-term investments for the quarter ending June 30, 2025 was $1.747B, a 56.28% decline year-over-year.
- Pfizer net change in short-term investments for the twelve months ending June 30, 2025 was $-2.520B, a 20.69% increase year-over-year.
- Pfizer annual net change in short-term investments for 2024 was $-2.869B, a 121.31% decline from 2023.
- Pfizer annual net change in short-term investments for 2023 was $13.464B, a 69.27% increase from 2022.
- Pfizer annual net change in short-term investments for 2022 was $7.954B, a 141.65% decline from 2021.
Pfizer Annual Net Change in Short-term Investments
(Millions of US $) |
| 2024 |
$-2,869 |
| 2023 |
$13,464 |
| 2022 |
$7,954 |
| 2021 |
$-19,098 |
| 2020 |
$-1,798 |
| 2019 |
$9,273 |
| 2018 |
$1,987 |
| 2017 |
$-2,236 |
| 2016 |
$9,239 |
| 2015 |
$17,251 |
| 2014 |
$350 |
| 2013 |
$-5,911 |
| 2012 |
$2,743 |
| 2011 |
$6,603 |
| 2010 |
$567 |
| 2009 |
$12,808 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$140.774B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
